Core Viewpoint - The announcement highlights that Zhongyuan Qihua's subsidiary, Zhongyuan Weikang, has received a Class III medical device registration certificate for a gene mutation detection kit, marking a significant advancement in tumor companion diagnostics in China [2][4]. Group 1: Medical Device Registration Details - The product is a human EGFR/KRAS/BRAF/ERBB2/PIK3CA gene mutation detection kit using time-of-flight mass spectrometry, with registration number Guo Xie Zhu Zheng 20263400419 and a validity period of five years [6]. - It is intended for the qualitative detection of gene mutations in formalin-fixed paraffin-embedded (FFPE) tissue samples from patients with non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) [6][10]. Group 2: Clinical Application and Impact - This kit is the first tumor companion diagnostic kit based on time-of-flight mass spectrometry approved for market use in China, providing precise diagnostic support for lung and colorectal cancer patients [7]. - The approval enhances the company's product line in tumor companion diagnostics and molecular pathology, thereby strengthening its competitive edge and market expansion capabilities [7]. Group 3: Strategic Significance - The approval integrates mass spectrometry technology into the regulatory framework for molecular diagnostics, which has traditionally been dominated by PCR and NGS technologies [13][15]. - The company’s strategy focuses on "precision medicine," encompassing molecular diagnostics and related reagent products, with this product approval marking a significant step in compliant promotion within the molecular diagnostic tool system [14].